Great Bay Bio Showcases AI-Driven Biologics Platform at JUMPSTARTER 2025 Global Summit
GBB
AI Biomedical R&D Company
Recently, the JUMPSTARTER 2025 International Summit, one of the largest and most anticipated events in Asia's innovation and technology industry, was successfully held in Hong Kong.GBB was invited to participate in this summit, showcasing how the company, under the acceleration of capital, rapidly advances technological upgrades and global commercial layout.
▲JUMPSTARTER 2025 International Summit
This JUMPSTARTER 2025 Tech Innovation Gala has invited renowned speakers from various industries, including venture capital, academia, entrepreneurs, technology experts, and leaders from different sectors, to jointly explore the impact of AI on business and gain valuable insights into investments for future development.
Headquartered in Hong Kong Science Park, the largest technology research and development and enterprise incubation base in Hong Kong, GBB utilizes cutting-edge technologies such as AI to provide end-to-end empowerment for early drug discovery and subsequent bioprocess development. The process from target/antibody drug discovery to early CMC takes only 8 months, addressing various pain points in global biopharmaceutical development, including long cycles, high costs, and low success rates.In the process of realizing the vision of "making global bioprocess development simpler and more efficient," GBB has continuously gained favor from capital in the biotechnology and AI fields, further advancing its global commercial layout.
In the international market, GBB has reached strategic cooperation with several large multinational enterprises in the fields of life sciences, specialty chemicals, and pharmaceutical CDMOs. Its clients are spread across different regions including Europe, North America, South America, and Asia, meeting the global biopharmaceutical industry's demand for rapid development and production of new products.GBB has successfully assisted clients in obtaining approval from the National Medical Products Administration (NMPA) of China and the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), with the first clinical dose already administered.
▲GBB Products Debut at JUMPSTARTER 2025 International Summit
▲GBB Team Attends JUMPSTARTER 2025 International Summit
In the future, we will continue to expand our R&D investment and team size, deepen strategic collaboration with international partners, allow innovative technologies to radiate globally from Hong Kong, promote the advancement of our internationalization strategy, and deliver returns to the capital market.
Tel: 400 079 8808
18926497707 (Same number on WeChat)
Email: BD@greatbay-bio.com
